Lv1
60 积分 2025-04-09 加入
A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials
1个月前
已关闭
Evaluating tezepelumab for COPD: a missed target or unmet potential?
1个月前
已完结
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
1个月前
已完结
皖公网安备34019202002308
